

# TAK-003 for Travelers: Insights from Japanese Travel Medicine Providers

## Descriptive study



May 31 to June 30, 2024



TAK-003 (Qdenga®)

Dengue



**Opinions and decision-support information among travel medicine providers is limited**



Surveyed 154 travel medicine providers in Japan for opinions regarding Qdenga vaccine that has not yet been approved in the country



## High willingness to accept TAK-003:



Long-term travel



Short-term travel



## High recommendations for TAK-003:



Long-term travel




Short-term travel



## Main concerns for non-recommendation:



Efficacy



Antibody-dependent enhancement risk



Adverse reactions



## Need for decision-support in dengue vaccine recommendations

- Scientific evidence on safety and efficacy
- Data on dengue-endemic regions
- International vaccination guidelines

Atsuko Fukunishi, Masaki Machida, Shinji Fukushima, Shigeru Inoue.  
Travel medicine providers' opinions on the dengue vaccine TAK-003 as a travel vaccine and the need for decision-support information and materials before its launch in Japan.

Hum Vaccin Immunother. 21(1):2483560. 2025

DOI: [10.1080/21645515.2025.2483560](https://doi.org/10.1080/21645515.2025.2483560)

This work is licensed under [CC BY-NC 4.0](https://creativecommons.org/licenses/by-nc/4.0/)